Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Shaum M Kabadi"'
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer (AVC). Although BTC is rare in the US, incidence is increasing and elevate
Externí odkaz:
https://doaj.org/article/e1bd953cc4b3429fa9885ccc59e9867e
Autor:
Katherine Baria, Enrico N. De Toni, Binbing Yu, Zhuoxin Jiang, Shaum M. Kabadi, Matteo Malvezzi
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 4, Pp 618-626 (2022)
Background and Aims: Biliary tract cancer (BTC) consists of a group of hepatic and perihepatic tumors that are in close proximity but are anatomically different, including gallbladder cancer (GBC), cholangiocarcinoma (extrahepatic and intrahepatic [I
Externí odkaz:
https://doaj.org/article/78683ed8292d4836aeff6b805d97894e
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Abstract Background Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population‐based retrospective cohort study to
Externí odkaz:
https://doaj.org/article/ee10a73acaf446daa5e76ae59e569ae3
Autor:
Narendranath Epperla, Melissa Pavilack, Temitope Olufade, Richa Bashyal, Jieni Li, Shaum M. Kabadi, Huseyin Yuce, Leslie Andritsos
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background Purine nucleoside analogs (PNAs) are the recommended first-line treatment for patients with hairy cell leukemia (HCL), but they are associated with adverse events (AEs). Due to a lack of real-world evidence regarding AEs that are
Externí odkaz:
https://doaj.org/article/3c5dd0d2d00a4cb6a5d2bb070412bf25
Publikováno v:
Cancer Medicine, Vol 8, Iss 17, Pp 7174-7185 (2019)
Abstract Introduction There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL). Methods Adults with ≥1 treatment for MCL between 1 Novem
Externí odkaz:
https://doaj.org/article/0accf50d413c4b4fbffeb6313fb00341
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3803-3810 (2019)
Abstract Introduction Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed tre
Externí odkaz:
https://doaj.org/article/8f0d4103cfdf4d6096dda24a3ec502d5
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Background Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population‐based retrospective cohort study to assess OS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::635e2735f2b6f45345be03c91524bbe4
https://doi.org/10.1002/cam4.3855
https://doi.org/10.1002/cam4.3855
Autor:
Usama Gergis, Charlie Nicholls, Praveen Potukuchi, Shaum M Kabadi, Deepika Verma, Nayan Patel, Olivia Li, Andrew Milgroom, Jeffrey R Skaar, Jonathan Ieyoub
Publikováno v:
Blood. 140:12869-12870
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9261b31fea6efe5217259931b34f4df
https://doi.org/10.1182/blood-2022-167993
https://doi.org/10.1182/blood-2022-167993
Publikováno v:
Advances in Therapy. 37:3129-3148
Amidst a changing treatment landscape, real-world evidence on the burden of chronic lymphocytic leukemia (CLL) is limited. The purpose of this study was to describe treatment patterns, adverse events (AEs), and economic burden among treated patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19b83f7ab4c5e8baf91c086c1ed2788
https://doi.org/10.1007/s12325-020-01350-w
https://doi.org/10.1007/s12325-020-01350-w
Autor:
Shaum M Kabadi, Danielle Potter, Aliki Taylor, Mark F Riffon, Brittany Manning, Robert S. Miller, Cathy Emmas, Miao Jiang
Publikováno v:
JCO clinical cancer informatics. 5
PURPOSE In 2014, the ASCO developed CancerLinQ (CLQ), a health technology platform for oncology. The CLQ Discovery (CLQD) database was created to make data available for research and this paper provides a summary of this database. METHODS This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d03412720025121e889d8f67da48e1
https://pubmed.ncbi.nlm.nih.gov/34110931
https://pubmed.ncbi.nlm.nih.gov/34110931